Pharmacokinetics of Oral Hydroxyurea Solution

NCT03763656 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Sickle-Cell; Hemoglobin Disease, Thalassemia
Sickle Cell-beta-thalassemia
Sickle Cell Hemoglobin C

Interventions

DRUG: Oral Hydroxyurea (100 mg/mL) Solution

Sponsor

Nova Laboratories Limited